<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01156168</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000681004</org_study_id>
    <secondary_id>ECOG-E2100T4</secondary_id>
    <nct_id>NCT01156168</nct_id>
  </id_info>
  <brief_title>Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab</brief_title>
  <official_title>VEGF Gene Amplification/Deletion and Haplotype as Biomarkers for Bevacizumab in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will&#xD;
      respond to treatment.&#xD;
&#xD;
      PURPOSE: This research study is studying biomarkers in tissue samples from patients with&#xD;
      breast cancer treated with bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To demonstrate that vascular endothelial growth factor-A (VEGFA) haplotypes that are&#xD;
           associated with an increased VEGFA expression will predict superior outcome for patients&#xD;
           with metastatic breast cancer receiving bevacizumab in ECOG-E2100 (but not for the&#xD;
           control arm).&#xD;
&#xD;
        -  To demonstrate that candidate single nucleotide polymorphisms (SNPs) will further&#xD;
           improve the predictive capacity of outcome (efficacy and toxicity) in patients enrolled&#xD;
           in ECOG-E2100.&#xD;
&#xD;
        -  To demonstrate that tumor VEGFA amplification or borderline amplification (estimated 14%&#xD;
           frequency) will predict superior outcome for patients with metastatic breast cancer&#xD;
           receiving bevacizumab on ECOG-E2100 whereas those with VEGFA deletion (estimated 11%&#xD;
           frequency) will predict inferior outcome.&#xD;
&#xD;
        -  To demonstrate that VEGFA amplification/deletion will not predict outcome in the control&#xD;
           arm of ECOG-E2100.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To demonstrate that tumor VEGFA amplification will predict increased protein expression&#xD;
           as ascertained by IHC.&#xD;
&#xD;
        -  To demonstrate that a combined algorithm calculated from tumor-specific variability&#xD;
           (VEGFA amplification/deletion) and host-specific variability (SNPs) will optimally&#xD;
           predict outcome (efficacy) with bevacizumab in patients enrolled on ECOG-E2100.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Previously collected tumor-derived DNA is analyzed for VEGFA amplification/deletion and&#xD;
      haplotype as biomarkers for outcome after bevacizumab treatment. Gene expression,&#xD;
      polymorphism, protein expression analysis, and IHC are performed on the samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 2011</start_date>
  <completion_date type="Actual">September 8, 2011</completion_date>
  <primary_completion_date type="Actual">September 8, 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between VEGF haplotype and median overall survival (OS) and grade 3/4 hypertension (HTN)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between VEGF amplification/deletion and VEGF expression</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">363</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Samples from patients enrolled on E2100 from whom samples were submitted for research&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Enrolled on ECOG-E2100&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan P. Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University Melvin and Bren Simon Cancer Center</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

